Haemonetics Corporation · NYSE:HAE
Haemonetics — Q2 2027 Earnings Presentation
19 slides from Haemonetics's earnings presentation, Nov 5, 2026
Slide 1: Second Quarter Fiscal 2027 Results
Second Quarter Fiscal 2027 Results November 5, 2026 © 2026 Haemonetics Corporation
Slide 2: Q2 Fiscal 2027 Conference Call Detail
Q2 Fiscal 2027 Conference Call Detail Conference call will take place at CONFERENCE 8:00 a.m. ET on November 5, 2026, and CALL SPEAKERS can be accessed via live webcast: Link or teleconference : Link. The earnings release, accompanying Chris Simon slides and a replay of the conference President & CE
Slide 3: Important Information
Important Information Safe Harbor for Forward - Looking Statements Any statements contained in this presentation that do not describe historical facts may constitute forward - looking statements. F orward - looking statements in this presentation may include, without limitation, statements regarding
Slide 4: Q2 Fiscal 2027 Highlights
Q2 Fiscal 2027 Highlights Broad - based Major milestones advance Strong cash generation profitable growth our growth strategy expands financial flexibility $358M ✓ Expanded CSL relationship • CSL currently anticipates completing $128M +15% Y/Y REVENUE the rollout of NexSys ® with Persona ® OPERATING
Slide 5: PacePro guidewire broadens our TAVR reach while preserving SavvyWire's differentiated position
PacePro guidewire broadens our TAVR reach while preserving SavvyWire’s differentiated position A familiar, pacing - enabled workhorse wire expands physician choice through the same commercial infrastructure. PACEPRO STRATEGIC RATIONALE Engineered to perform. Cleared to pace. 01 Expands participation
Slide 6: PerQseal Elite FDA approval rounds out our vascular closure portfolio
PerQseal ® Elite FDA approval rounds out our vascular closure portfolio Coverage from 5F to 22F in sheath inner diameter, with large - bore arterial closure up to 26F arteriotomy size COMPLETE VASCULAR CLOSURE PORTFOLIO PERQSEAL ELITE OPPORTUNITY VASCADE® VASCADE MVP® VASCADE MVP® XL PerQseal ® Elit
Slide 7: Q2 Fiscal 2027 Revenue by Business Unit
Q2 Fiscal 2027 Revenue by Business Unit REVENUE REPORTED ORGANIC Q2 2027 Q2 2026 (in millions) GROWTH GROWTH 1 (in millions) Plasma $162.6 $139.6 16.5% 17.7% $327 $358 Other 2 $42.2 $42.2 - 0.2% Apheresis $204.8 $181.8 12.6% 13.6% MedSurg Interventional $60.5 $59.1 2.4% 3.2% Technologies 3 Apheresis
Slide 8: Q2 Fiscal 2027 Financial Review
Q2 Fiscal 2027 Financial Review GAAP RESULTS NON - GAAP RESULTS Q2 2027 Q2 2026 Y/Y Q2 2027 Q2 2026 Y/Y Adjusted Gross Margin % 61.7% 59.5% +220bps 61.9% 60.5% +140bps Gross Margin % Adjusted Operating Margin % 21.0% 17.9% +310bps 26.3% 26.7% - 40bps Operating Margin % Adjusted Net Net Income Margin
Slide 9: Q2 Fiscal 2027 Segment Performance
Q2 Fiscal 2027 Segment Performance APHERESIS MEDSURG Q2 2027 Q2 2026 Y/Y Q2 2027 Q2 2026 Y/Y 12.6% 5.1% reported / reported / Revenue $204.8M $181.8M Revenue $153.0M $145.5M 13.6% 5.5% organic organic Segment Segment 30.5% 31.6% - 110bps 20.7% 20.5% +20bps Operating Margin % ¹ Operating Margin % ¹ 1
Slide 10: Balance Sheet and Cash Flow Metrics
Balance Sheet and Cash Flow Metrics CASH FROM OPERATIONS (in millions) 9/26/26 3/28/26 (dollars in millions) $345 FCF CapEx & Other 4 $289 Cash & cash $83 $261 $245 equivalents $73 Working capital $555 $552 $180 Total debt $1,124 $1,225 $38 $128 $129 $111 $262 $24 $38 $216 Net debt 1 $863 $979 $23 $
Slide 11: Full-Year Fiscal 2027 Guidance
Full - Year Fiscal 2027 Guidance GUIDANCE AS OF GUIDANCE AS OF AUGUST 6, 2026 NOVEMBER 5, 2026 Reported Revenue 5 – 8% 8 – 11% 53rd Week Impact (~2%) (~2%) Strategic exits 1 ~1% ~1% Currency Impact 0 – 1% 0 – 1% Organic Revenue 2 4 – 7% 6 – 9% Apheresis LSD to MSD Growth HSD Growth MedSurg MSD Growt
Slide 12: Appendices
Appendices 12 © 2026 Haemonetics Corporation
Slide 13: Appendix A: Reconciliation of GAAP to Organic Revenue Growth Rates
Appendix A: Reconciliation of GAAP to Organic Revenue Growth Rates ($ millions) Reported Currency Acquisitions & Organic Q2 2027 Q2 2026 growth impact Divestitures 1 growth 2 Revenues by business unit Plasma $162.6 $139.6 16.5% (0.6%) (0.6%) 17.7% Other 3 $42.2 $42.2 – (0.2%) – 0.2% Apheresis $204.8
Slide 14: Appendix B: Reconciliation of GAAP to Non-GAAP Q2 Fiscal 2027 Financial Results
Appendix B: Reconciliation of GAAP to Non - GAAP Q2 Fiscal 2027 Financial Results Interest and Operating Provision Net income Earnings Operating other Gross profit for income per diluted ($ millions) expenses income (expense ) (Loss) taxes share income Reported $220.9 $145.8 $75.1 ($12.3) $16.6 $46.
Slide 15: Appendix B: Reconciliation of GAAP to Non-GAAP Q2 Fiscal 2026 Financial Results
Appendix B: Reconciliation of GAAP to Non - GAAP Q2 Fiscal 2026 Financial Results Interest and Provision for Earnings Operating Operating Net Gross profit other income per diluted ($ millions) expenses income income expense taxes share Reported $194.7 $136.3 $58.5 ($7.2) $12.6 $38.7 $0.81 Amortizati
Slide 16: Appendix C: Reconciliation of Cash Flows
Appendix C: Reconciliation of Cash Flows ($ millions) Q2 2027 Q2 2026 FY 2027 FY 2026 Free Cash Flow Reconciliation Cash provided by operating activities $128.1 $111.3 $180.4 $128.7 Capital expenditures ($14.8) ($5.0) ($22.7) ($8.8) Additions to Haemonetics equipment ($10.1) ($17.7) ($15.7) ($29.1)
Slide 17: Appendix D: Reconciliation of Segment Operating Income to Net Income (1 of 2)
Appendix D: Reconciliation of Segment Operating Income to the Total Company Net Income (1 of 2) ($ millions) Q2 2027 Q2 2026 Net revenues: Apheresis $204.8 $181.8 MedSurg $153.0 $145.5 Total net revenues $357.8 $327.3 Significant segment expenses and operating performance: Apheresis Cost of goods so
Slide 18: Appendix D: Reconciliation of Segment Operating Income to Net Income (2 of 2)
Appendix D: Reconciliation of Segment Operating Income to the Total Company Net Income (2 of 2) ($ millions) Q2 2027 Q2 2026 Corporate and unallocated expenses Amortization of acquired assets ($10.4) ($13.2) Integration and transaction costs ($2.6) ($1.5) Restructuring and restructuring related cost
Slide 19: Appendix E: Reconciliation of GAAP to Non-GAAP of TTM Financial Results
Appendix E: Reconciliation of GAAP to Non - GAAP of TTM Financial Results 1 TTM Q2 TTM Q2 FY27 Net FY26 Net ($ millions) income income (loss) (loss) Reported $103.9 $168.2 Amortization of acquired intangible assets $32.5 $34.5 Amortization of fair value inventory step up $1.0 $7.9 Acquisition, Integ